SEATTLE, March 19, 2021, (MEDGADGET) — For surgical incision, suture and stapled are commonly practiced devices. Although both the techniques are effective, they both pose certain risks such as scars and infections. Sutures are time-consuming and cost effective, on the contrary staples offer more consistent and rapid solution. Advancement in technology has offered new techniques such as absorbable, tapes, and adhesive compounds. Moreover, these devices are available in different materials.
Note: *The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.
Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/50
Cold plasma offers great advantages over the conventional methods including watertight tissue seal, elimination of a foreign-body reaction to sutures or clips, reduction in surgical procedure time, and reduction of trauma. A recent study conducted on porcine skin incisions demonstrated comparable and favorable wound healing results macroscopically as well as histopathologically. There wasn’t any epidermal damage, infection, bleeding, and wound dehiscence detected on at the incision site.
Selection of an apt technique or device is essential for optimal healing.
IonMed, an Israel-based company, received the U.S. Food and Drugs Administration (FDA) approval for its new cold plasma based surgical incision closure device called BioWeld1. Plasma has shown diverse benefits in tissue welding such as enhancement of tissue repair, disinfection, control of bleeding, and destruction of cancer cells. However, due to high temperature of plasma, it results in harmful effects on the body tissues. Therefore, scientists at IonMed found a way to use cold plasma for effective and safe sealing of wounds. The process takes a few minutes but leaves minimal scars. The device can be used for skin grafts along with its bioadhesive tape – Chitoplast strips. The combined action of bioadhesive and plasma provides the basis for natural healing process.
In 2014, IonMed received CE mark for BioWeld1 and the clinical trials got completed in 2015. Once the product has the CE clearance, it can also be used in skin grafts and traumatic wounds. The product is being used in the U.S. and will be commercialized extensively in the Europe too.
Exclusive offer!!! Purchase the report at a discounted rate!!!
Apply Promo Code “CMIFIRST1000” and Get Up to 30% Discount
Quick Buy – Cold Plasma Bio-welding Device Market Research Report: https://bit.ly/3c0kc0X
According to the Trendlines Group, an innovation commercialization company, there are around 5 million skin grafts annually conducted in the EU. Moreover, there are nearly 70 million surgeries conducted annually in the Unites States requiring incision closures. Moreover in the U.K., there are around 5.89 million surgeries where wound closure devices could be used. Even if a small percentage of these surgeries start using this device, could be a great start for cold plasma surgical incision device. The potential thus is very huge for cold plasma bio-welding devices like BioWeld1 which offers great advantages over the conventional staples and sutures.
Key players operating in the global Cold Plasma Bio-welding Device are Ethicon, Inc., Baxter International, Inc., 3M Company, Covidien PLC, Coloplast A/S, and Smith & Nephew need to come up with new technologies and compete with such advanced and better devices to sustain their market share.
Cold plasma could prove to be beneficial in expediting wound closure, tissue healing, attaining positive outcomes and providing sufficient tensile strength. Continuous investment is required to make the cold plasma bio-welding device BioWeld1, widely available.
To get detailed table of content (ToC), please click – https://www.coherentmarketinsights.com/ongoing-insight/toc/50
Major market players in the market involved in various growth strategies such as product approvals from regulatory authorities, in order to expand their product portfolio. For instance, in August 2019, the U.S. FDA approved a US Medical Innovations LLC-developed cold atmospheric plasma system ‘Canady Helios Cold Plasma System and Scalpel’ for human clinical trials.
Major institutes are also focused on research and development activities related to cold plasma bio-welding technology. For instance, in September 2019, researchers from University of Antwerp, Belgium, evaluated the influence of the cell type, cancer type, and cell culture medium on direct and indirect cold atmospheric plasma treatment.
Similarly in August 2019, researchers from Leibniz Institute for Plasma Science and Technology found that plasma treatment is a safe and promising therapeutic option and that it does not promote metastatic behavior in pancreatic cancer cells in vitro and in ovo.
Table of Content
Global Cold Plasma Bio-welding Device Market Research Report
Section 1: Global Cold Plasma Bio-welding Device Industry Overview
Section 2: Global Economic Impact on Cold Plasma Bio-welding Device Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Cold Plasma Bio-welding Device Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Cold Plasma Bio-welding Device Market Forecast
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027